Biowa Signs License Agreement With Merck

BioWa has entered into a license agreement with Germany-based Merck (with access to BioWa’s Potelligen Technology platform) for the research, development and commercialization of their antibody therapies, with enhanced antibody-dependent cellular cytotoxicity (ADCC).

Under the terms of the license agreement, BioWa grants Merck non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent Technology, for an undisclosed number of targets.

In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products.

Masamichi Koike, president and CEO of BioWa, said: We are extremely pleased about our partnership with Merck. Merck’s world-class R&D organization and global market presence will enable us to promote and extend the benefit of the technology to patients all over the world more efficiently.